ClinicaliQ Trial Snapshot
- Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors — Active Not Recruiting • Phase I • Oncology • NCT06545942.
- A study testing a new oral drug (MOMA-313) in patients with advanced cancers, assessing safety, dosage, and effectiveness alone or combined.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors. Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency Interventions: MOMA-313, Olaparib Lead Sponsor: MOMA Therapeutics Planned Enrollment: 220 participants